Arca
Skip to content
Tools
Tools

HGF: Hepatocyte growth factor

Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on HGF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2

Approved0

    Phase 32

    • Ficlatuzumab
    • Rilotumumab

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        FiclatuzumabPhase 3LG ChemAntibodyInhibitorHepatocyte growth factor inhibitor2
        RilotumumabPhase 3AmgenAntibodyInhibitorHepatocyte growth factor inhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
        A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaFiclatuzumabPhase 3RecruitingAVEO Pharmaceuticals, Inc.Oct 3, 2023
        Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaFiclatuzumabPhase 2 / Phase 3RecruitingBeat AML, LLCJan 9, 2017

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Hearing loss, autosomal recessive0.60
        • Gastric adenocarcinoma0.41
        • Gastroesophageal junction adenocarcinoma0.41
        • Lung carcinoma0.40
        • Cancer0.40
        • Deafness0.40
        • Esophageal adenocarcinoma0.39
        • Lung adenocarcinoma0.39
        • Gastric carcinoma0.38
        • Prostate carcinoma0.38
        • Neurodegenerative disease0.37

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5479, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14210, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.